MAXCYTE, INC. Income Statement
MXCT|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
MAXCYTE, INC. reported $33M in revenue and $45M in net loss for FY2025. Revenue has declined at a 0.6% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $33.0M | $41.3M | $44.3M | $44.3M | $33.9M |
| Cost of Revenue | $6.2M | $4.7M | $5.1M | $5.1M | $3.6M |
| Gross Profit | $26.8M | $36.5M | $39.2M | $39.2M | $30.2M |
| SG&A Expense | $28.1M | $30.1M | $25.8M | $25.8M | $18.7M |
| R&D Expense | $20.8M | $23.8M | $19.5M | $19.5M | $15.4M |
| Operating Income | -$51.9M | -$48.3M | -$27.4M | -$27.4M | -$18.2M |
| Interest Expense | - | - | - | - | $5.4K |
| Income Tax | - | - | - | - | $0 |
| Net Income | -$44.6M | -$37.9M | -$23.6M | -$23.6M | -$19.1M |
| EPS (Basic) | -$0.39 | -$0.37 | -$0.23 | -$0.21 | -$0.23 |
| EPS (Diluted) | -$0.39 | -$0.37 | -$0.23 | -$0.21 | -$0.23 |
| Shares Outstanding | 105.7M | 104.0M | 102.4M | 101.2M | 77.4M |
| Gross Margin | 81.2% | 88.5% | 88.5% | 88.5% | 89.2% |
| Operating Margin | -157.1% | -117.0% | -61.8% | -61.8% | -53.7% |
| Profit Margin | -135.1% | -91.8% | -53.3% | -53.3% | -56.3% |